Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€4.86
Target price
20.11.24
€9.15
Performance (%)
19.56%
Price
21.06.24
€5.99
Summary
This prediction is currently active. The prediction currently has a performance of 19.56%. This prediction currently runs until 20.11.24. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | 7.153% | 7.153% |
| iShares Core DAX® | 0.611% | -2.723% |
| iShares Nasdaq 100 | -0.208% | 6.703% |
| iShares Nikkei 225® | 1.298% | 1.009% |
| iShares S&P 500 | 0.636% | 5.035% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat